Tralokinumab
Tralokinumab (CAT354) is a humanized IgG4 monoclonal antibody that specifically binds to and neutralizes IL-13. Tralokinumab can be used in the research of diseases such as asthma, atopic dermatitis, and pulmonary fibrosis[1][2].
Product Specifications
CAS Number
1044515-88-9
Product Name Alternative
CAT354
UNSPSC
12352203
Target
Apoptosis; Cadherin; Caspase; Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Cytoskeleton; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tralokinumab.html
Purity
99.12
Solubility
H2O
Smiles
[Tralokinumab]
Molecular Weight
(144.14 kDa)
References & Citations
[1]A Wollenberg, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) . Br J Dermatol. 2021 Mar;184 (3) :437-449.|[2]Murray LA, et al. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. 2014 May;50 (5) :985-94.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Isoform
IL-13
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bs-3872R-BF647 100 µL
GATA1 Polyclonal Antibody, AbBy Fluor™ 647 Conjugated
Sign In for Pricing
View Details 